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Abstract
Introduction: Sickle cell disease (SCD) is one of the most devastating diseases ravaging
most populations.
Methodology, results, and discussion: The numerous plants earlier reported to be used
for treating SCD were compiled along with their geographical locations (using relevant
online  databases  when  not  provided  in  cited  articles  for  each  plant)  and  relative
antisickling strength. The process of hemolysis in sickle cell diseases, a brief overview
of the current treatments, and management of sickle cell diseases is considered in the
chapter.  The  activities  of  endogenous  antioxidants  and  some biochemical  enzyme
markers coupled to these plants’ ability to maintain the integrity of red blood cell
membrane are discussed in line with their antisickling health benefits and are also used
to  proffer  more  reliable  molecular  therapeutic  strategies  for  managing  sickle  cell
diseases. Furthermore, the operational principles of some enzymes, as well as their
contributions  to  advancement  of  knowledge for  management  of  the  disease,  were
examined.
Conclusion: Geographical spread of these identified antisickling plants contributes to
low levels of sickle cell patients where the potentials are known. More efforts should
therefore be channeled toward increasing awareness about the plants, as well as
harnessing their active principles to obtain a more lasting solution to sickle cell disease
at the molecular level.
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1. Introduction
Sickle cell disease (SCD) is an autosomal recessive genetic disorder that is caused by a mutation
in the β-globin gene on chromosome 11q [1]. This mutation involves glutamic acid being
substituted with valine at the 6th position along the β-globin chain. α2β2 is expressed as normal
hemoglobin, α2βS (heterozygote) is expressed as sickle trait, while α2S2 (homozygote recessive)
is expressed as sickle cell anemia. Most of the time as a result of repeated series of sickling and
unsickling, the erythrocytes become permanently damaged and consequently lyse. Some acute
and chronic tissue injuries result when these abnormally shaped red cells impede blood flow
through the vessels [2].
Sickle cell disease is one of the most devastating diseases ravaging most populations. It is a
disease that affects numerous nations and ethnic groups. It is associated with painful symp-
toms and is a genetic disease in which an individual inherits the allele for sickle cell hemoglobin
from both parents. Patients with this disease possess lower level of erythrocytes than the
normal healthy human. In addition to an unusually large number of immature cells such as
transferrin receptor-positive, reticulocytes, erythroblasts that sometimes manifest in the form
of granular bodies in the cytoplasm of red blood cells, the blood contains many long, thin,
crescent-shaped erythrocytes that look like the blade of a sickle [3]. The hemoglobin (hemo-
globin S) in blood of patients with sickle cell disease becomes insoluble and forms polymers
that aggregate into tubular fibers when deoxygenated. The altered properties of hemoglobin
S result from a single amino acid substitution, which leads to the presence of a valine (Val)
with no electric charge instead of a glutamate (Glu) residue with a negative charge when pH
is 7.4 at position 6 in the two chains, resulting in two fewer negative charges than normal
hemoglobin A [3]. Glutamine residue replaces the valine residue at position 6 of β-chain of
hemoglobin in the normal blood to form a “sticky” hydrophobic interaction outside the surface
of the sickle cell blood. It is the resultant sticky points on the surface of sickle cell blood that
makes deoxyhemoglobin S molecules to interact abnormally with each other to form the long,
fibrous aggregates peculiar to this disorder that eventually cause the deformation of the normal
disc biconcave red blood cell ’RBC’ [4].
Polymerization of the sickled cells thereby alters the integrity of the red cell membrane, leading
to loss of K+, water, and a corresponding gain of Na+. Increased intracellular free Ca2+ occurs
during sickling, resulting in a loss of K+ with accompanying movements of Cl- and water [5].
The clumping of sickled RBCs leads to blockage of small blood vessels, preventing blood
supply to various organs. The deoxygenation process in tissue capillaries causes damage to its
endothelium, leading to exudation of plasma into the surrounding soft tissue [6]. The integrity
of the red blood cell membrane is maintained by hydration and sickling is generated when
there is dehydration of the membrane. It is also believed that increase in synthesis of endog-
enous nitric oxide may be beneficial to SCD patients by preventing the mopping up of the nitric
oxide by the hemoglobin released during hemolysis, which may trigger a cascade of events
that ultimately inhibit blood flow [7].
There is high incidence of the sickle cell disease in different parts of the world, especially in
Africa and Asia. The traditional people in these regions have learnt to manage the problem
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using plants which are God’s gift of nature, especially among the lower socio-economic class
who cannot afford the high cost of western medicine, as well as traditionalists who simply
believe in their efficacy [6]. There has been increasing insight into gaining understanding about
the management approaches of sickle cell disease in several African countries on the efficacy
of conventional and traditional medicines. However, no substantial evidence exists to support
the efficacy of herbal medications in actually curing the disease. Research into phytotherapy
of diseases is a current trend in the management of sickle cell disease, with the hope of finding
inexpensive and less toxic alternative medicines that people can easily access [8].
Nutritional evaluation of S. monostachyus leaves revealed the presence of carbohydrate,
protein, ash, fiber, and fat as well as potassium and vitamin C in higher concentrations; calcium,
magnesium, vitamin A, vitamin B6, vitamin E in lower concentrations; and others in trace
quantities. Phytochemical screening revealed the presence of tannins, saponins, alkaloids,
flavonoids, cyanogenic glycosides, and phytate [9]. Caffeic acid is one of the bioactive phenolic
components of Solenostemon monostachyus leaves (unpublished report). It is a potent antioxi-
dant. The study of antioxidants especially in various antisickling agents is of great significance
because antisickling agents vary in their degree of efficacy. Antioxidants constitute a major
component of these antisickling agents; thus, it is believed that the higher the antioxidant
property of an antisickling agent, the higher its possible antisickling and therapeutic effect.
Thus, reducing oxidative stress may ameliorate sickle cell crisis [8].
As a reference point, African/Nigerian medicinal plants are applied in the treatment of
diseases, such as HIV/AIDS, malaria, tuberculosis, sickle cell diseases, diabetes, mental
disorders, and so on. Research on these medicinal plants has shown various results such as
antimicrobial (16%), molluscicidal (11%), antimalarial (7%), plant toxicology (7%), antitumor
(4%), and many others. The major challenge with these medicinal plants is the lack of
scientifically based evidence, quality standards, and regulations [6]. The antisickling activity
of S. monostachyus on human sickle blood cells resulting in the alleviation of SCD symptoms
has been reported [10]. Sickle cell disease and thalassemia are hemoglobinopathies character-
ized by chronic hemolysis [11].
2. Contribution of phytomedicine in the management of sickle cell
diseases
The use of medicinal plants in the control of many diseases such as sickle cell diseases may be
useful, especially in developing countries. The cost of treatment provided by orthodox medical
practitioners largely contributes to the dependence on the use of traditional medicine in low-
income settings. Much of the medicinal use of plants seems to have been developed through
observations of wild animals, and by trial and error. It has been estimated by the World Health
Organization that 80% of the world’s population relies on traditional medicine to meet their
daily health needs. Thiocyanate-rich foods, erythropoietin, nutritional supplements, food
extracts, phytochemicals, and synthetic compounds have been tested in vitro and in vivo on
their possible roles in the management of sickle cell disease [12]. Many medicinal plants with
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antisickling properties are indicated in Table 1. The leaves from most of the above-identified
plants have been successfully proven to play a role in the management of sickle cell diseases
possibly by antioxidant phytochemicals, proximate nutrients, amino acids, and minerals.
Phytochemical testing revealed the presence of folic acid, vitamin B12, alkaloids, spooning,
glycosides, tannins, and anthraquinones. Studies also indicated the plant extracts contained
flavonoids and the antioxidants vitamins A and C [13, 14].
S.n  Natural antisickling
resources
Name of country
where identified
Natural habitat and geographical locations References
1 Zanthoxylum
zanthoxyloides (Fagara)
root
Nigeria Senegal and other west African countries [23]
2 Cajanus cajan seeds Nigeria West/South Africa, southern India, and northern
Australia
[24, 25]
3 Solenostemon
monostachyus (P. Beauv.)
Briq.
Nigeria Anthrogenic habitat and rocky savanna in
Cameroon, Gabon, Equatorial Guinea, Ivory
Coast, Benin, Nigeria, Liberia, Guinea, Ghana,
Togo, Burkina Faso, Republic of the Congo, Sao
Tome and Principe, Central African Republic,
Mali, and Brazil
[10]
4 Ipomea involucrata Nigeria Tropical Asia (possibly India); South and South-
East Asia, tropical Africa, South and Central
America; and Oceania
[10]
5 Carica papaya seed oil Nigeria Originated in Central America and is now grown
in tropical areas worldwide
[10]
6 Carica papaya unripe fruit Nigeria Originated in Central America and is now grown
in tropical areas worldwide
[13, 26]
7 Parquetina nigrescens
(whole plant extracts)
with ability to boost
blood volume
Nigeria A large part of Africa, from Senegal east to Sudan
and south through Central and East Africa to
Zambia, Angola and eastern Zimbabwe
[27]
8 Nicosan (drug) Nigeria Commercially distributed by National Institute
for Pharmaceutical Research and Development
(NIPRD), Nigeria
[8, 15, 19, 28]
9 Ciklavit (drug) Nigeria Commercially distributed by Neimeth
International Pharmaceuticals Plc, Lagos, Nigeria
[8, 24, 29, 30]
10 Walthera indica
(Malvaceae)
Nigeria Widely distributed across tropical part of the
world.
11 Dried fish (Tilapia) and
dried prawn (Astacus red)
Nigeria Globally [31–33]
12 Fermented Sorghum
bicolor leaves
Nigeria Widely cultivated in tropical part of Africa and
Asia
[12]
13 Terminalia catappa
(Tropica Almond)
Nigeria Well-distributed globally but has abundant
presence in regions between Seychelles and
India; Southeast Asia; Papua New Guinea and
Northern Australia; South Pacific Region; China,
Taiwan, Cambodia, and New Caledonia
[12]
14 Scoparia dulcis Linnaeus Nigeria Tropical America and South-East Asia [34]
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S.n  Natural antisickling
resources
Name of country
where identified
Natural habitat and geographical locations References
15 Zanthoxylum macrophylla
(aqueous extract of
roots)
Nigeria Savannah and dry forest vegetation of
Southwestern Nigeria
[35, 36]
16 Garcinia kola (aqueous
extracts)
Nigeria Tropical rain forests with moist lowland
especially
in part of west Africa
[37, 38]
17 Adansonia digitata (bark) Nigeria Africa, Madagascar, and Australia [37, 39]
18 Fagara zanthoxyloides (root
extracts)
Nigeria West Africa and Cameroon [40, 41]
19 Vernonia amygdalina
(extracts)
Nigeria Tropical Africa and Asia [42]
20 Parquetina nigrescens Nigeria Most part of Africa
21 Grape (Citrus paradise) Nigeria Tropical and subtropical part of the world [10]
22 Lemon grass
(Citrus lemon)
Nigeria Widely distributed globally particularly in
Mediterranean region
23 Pumpkin, Telfeira
occidentalis (fresh leaves)
Nigeria Forest zone of West and Central Africa,
particularly in Benin (Nigeria)
and Cameroon
[8]
24 Pterocarpus santolinoides
DC
Nigeria Africa and South America [43]
25 Aloe vera Nigeria Indigenous to most parts of Africa,
widely distributed in the tropical and
subtropical regions of the world
[43]
26 Alchornea cordifolia Democratic
Republic of
Congo
West and Central Africa [44–47]
27 Afromomum albo violaceum Democratic
Republic of
Congo
West and Central Africa [48]
28 Annona senegalensis Democratic
Republic of
Congo
West and Central Africa. [49]
29 Cymbopogon densiflorus Democratic
Republic of
Congo
Widely distributed across the globe [50]
30 Bridelia ferruginea Democratic
Republic of
Congo
West Africa [50]
31 Ceiba pentandra Democratic
Republic of
Congo
Tropical regions of America and Africa [50]
32 Morinda lucida Democratic
Republic of
Congo
West and Central Africa [50]
33 Hymenocardia acida Democratic
Republic of
Congo
Tropical region of Africa [50]
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S.n  Natural antisickling
resources
Name of country
where identified
Natural habitat and geographical locations References
34 Coleus kilimandcharis Democratic
Republic of
Congo
Subtropical and warm temperate region
of India, Nepal, Myanmar, Sri Lanka, Thailand,
and Africa
[50–52]
35 Dacryodes edulis Democratic
Republic of
Congo
Rainforests of Central and West Africa,
particularly Angola, Benin, Cameroon, Central
African Republic, Congo, Cote d’Ivoire,
Democratic Republic of Congo, Equatorial
Guinea, Gabon, Ghana, Liberia, Nigeria, Sierra
Leone, Togo, and Uganda
[50]
36 Caloncoba welwithsii Democratic
Republic of
Congo
Tropical forest of Africa, particularly in West
Africa
[50]
37 Vigna unguiculata Democratic
Republic of
Congo
Originated in Africa. Present across the globe
particularly in savanna regions of West and
Central Africa
[50]
Table 1. Geographical locations of some identified antisickling plants.
The use of phytomaterials such as Piper guineense, Pterocarpus osun, Eugenia caryophyllata, and
Sorghum bicolor extracts in the drug Nicosan, previously NIPRISAN (Nix-0699), for the
treatment of sickle cell disease was reported to possess antisickling properties. Nicosan was
developed by a research team led by Prof. Charles O. Wambebe at the National Institute for
Pharmaceutical Research and Development, Abuja, Nigeria. The efficacy of the drug had been
reported with minor fear of toxicity since the constituents are largely from commonly con-
sumed food items such as Piper guineense, Eugenia caryophyllata, and Pterocarpus osun [15–19].
A major constituent of a herbal formula (Ajawaron HF) consists of the extracts of the roots of
Cssus populnea L. CPK had also been effectively used to reverse sickling in the management of
sickle cell disease in south west of Nigeria. The most prominent and widely used of them all
is Ciklavit developed by Prof G. Ekeke after 18 years of intensive research in collaboration with
Neimeth Pharmaceuticals, Lagos, Nigeria. These efforts led to the development of WHO-
approved drugs such as Niprisan and Ciklavit from some of these plants traditionally
identified for treating sickle cell diseases [8, 20, 21].
The role of other components in Ciklavit (apart from Cajanus cajan) is essentially nutritional.
A study on children with sickle cell disease suggests that nutritional supplements can help
improve growth and weight gain. It can also boost the immune system and thus help in
protecting against bacterial infections. Zinc deficiency is a major nutritional problem seen in
sickle cell disease [8, 22]. Also reported are amino acids, glycine, phenylalanine, and tyrosine,
which have been reported to possess antisickling properties. Particularly, extracts from
underutilized plants such as S. monostachyus, Carica papaya seed oil, and Ipomoea involucrata
were proven to reverse human sickle cell blood almost completely coupled with the ability to
also reduce stress in sickle cell disease patients. Hence, each plant individually or in combi-
nation can be used in the management of sickle cell disease [10].
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Local mixtures of herbivores, pollinators, and micro-organisms generated from the application
of plants usually upregulate or downregulate certain biochemical pathways. These actions are
often a result of their secondary metabolites as well as pigments, which can be refined to
produce drugs [53]. Many drugs originally derived from plants, such as salicylic acid (a
precursor of aspirin) originally derived from white willow bark and the meadowsweet plant,
have been developed using this approach. Quinine—antimalarial drug, Vincristine—an
anticancer drug, and drugs (morphine, codine, and paregoric) for treating diarrhea were
developed from Cinchona bark, periwinkle, and the opium poppy, respectively [54].
3. Plants as sources of antioxidants in the management of sickle cell
diseases
In addition to depletion in iron level, the generation of reactive oxygen species (ROS) in the
erythrocytes is a major factor contributing to the occurrence of anemia in sickle cell diseases.
ROS are defined as substances generated by one electron reduction of molecular oxygen,
including oxygen radicals and reactive nitrogen species (RNS) [55]. Common radical species
include peroxide, superoxide, and the hydroxyl radical that contain an unpaired electron and
as such are extremely reactive, allowing them to react immediately with any biological
molecule to produce cellular damage. ROS contributes to the pathogenesis of several heredi-
tary disorders of erythrocytes, including sickle cell disease, thalassemia, and glucose-6-
phosphate dehydrogenase (G6PD) deficiency. Oxidative stress is defined as the imbalance
between pro-oxidants and antioxidants, which is a result of the formation of reactive oxygen
species (ROS) in excess of the capacity of antioxidants to remove them [56].
3.1. Antioxidants
Antioxidants are the first line of defense against free radical damage and are critically needed
for the maintenance and optimization of human health and well-being. Defence mechanisms
against free radical-induced oxidative stress involve: (i) preventative mechanisms, (ii) repair
mechanisms, (iii) physical defenses, and (iv) antioxidant defences. The body is also equipped
with natural enzymatic antioxidant defences that include superoxide dismutase (SOD),
glutathione peroxidase (GPx), and catalase (CAT). Antioxidants terminate these chain reac-
tions by removing free radical intermediates and inhibit other oxidation reactions (Figure 1).
They do this by being oxidized themselves, so antioxidants are often reducing agents such as
thiols, ascorbic acid, or polyphenols [57].
In order to protect the cells and organ systems of the body against reactive oxygen species, a
highly sophisticated and complex antioxidant protection system has been evolved by humans.
This involves a variety of components such as nutrient-derived antioxidants, antioxidant
enzymes, metal-binding proteins, and numerous other antioxidant phytonutrients, which are
both endogenous and exogenous in origin, that function interactively and synergistically to
neutralize free radicals [59]. The natural antioxidants are naturally occurring antioxidants
having high or low molecular weights and can differ in their physical and chemical properties.
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The mechanisms by which these antioxidants act at molecular and cellular levels include role
in gene expression and regulation, apoptosis, and signal transduction. Thus, antioxidants are
involved in fundamental metabolic and homeostatic processes [58]. General patterns of
behavior of some endogenous antioxidant enzymes and other relevant enzymes associated
with sickle cell disease patients are subsequently described to provide more insight into how
to solve the numerous challenges of the disease. Furthermore, introduction to a few selected
enzymes that uniquely interact with constituents in these medicinal plants and are more
relevant to the advancement of sickle cell diseases are provided subsequently.
Figure 1. Pathways of ROS formation, the lipid peroxidation process, and the role of glutathione (GSH) and other anti-
oxidants (vitamin E, vitamin C, lipoic acid) in the management of oxidative stress (equations are not balanced) [58].
3.2. Glucose-6-Phosphate Dehydrogenase (G6PD)
Glucose-6-phosphate dehydrogenase (G6PD) is the limiting enzyme that catalyzes the first
reaction in the pentose phosphate pathway (Figure 2) in which glucose is converted into the
pentose sugars required for glycolysis and various biosynthetic reactions. The pentose
phosphate pathway (also known as the HMP shunt pathway) has a major biochemical role of
providing reducing power to all cells in the form of NADPH (reduced form of nicotinamide
adenine dinucleotide phosphate). This is possible in the presence of enzyme G6PD and 6-
phosphogluconate dehydrogenase. NADPH enables cells to neutralize oxidative stress often
induced by several oxidant agents and to preserve the reduced form of glutathione [57]. The
hemoglobin in the blood, enzymes, and other proteins are damaged by the oxidants after all
the leftover reduced glutathione is consumed. This leads to the generation of cross-bonding,
protein deposition, and electrolyte imbalance in the red cell membranes. The hemoglobin from
damaged red blood cells is metabolized to bilirubin that causes jaundice after attaining high
concentrations [60]. High incidence of G6PD has been associated with areas of high prevalence
of sickle cell disease. G6PD deficiency screening among SCD patients has provided the
opportunity to administer appropriate preventive and therapeutic measures. The enzyme is
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becoming an increasingly strong confirmatory indicator of blood associated with sickle cell
diseases and other closely associated ailments like malaria [10, 61]. The enzyme provides
information on the link between malaria and sickle cell diseases so as to understand strategies
for the adoption of resistance of SCD patients to malaria to improve human health.
Figure 2. The pentose phosphate pathway. Source: [60].
3.3. Heme oxygenase
Heme oxygenases (HO) consists of a family of evolutionarily conserved endoplasmic reticu-
lum (ER) enzymes [62]. Heme oxygenase (HO) plays a central role in regulating the levels of
intracellular heme by catalyzing the oxidative degradation of heme into equimolar amounts
of biliverdin, carbon monoxide, and iron as shown in Figure 3a and b [63]. They are central in
determining what happens with regard to the central components of mammalian stress
response and defense against oxidative stress [64]. Heme oxygenase activity is a key determi-
nant of the health status of sickle cell anemia patients. Human sickle blood enhances endo-
thelial heme oxygenase (HO) activity and the positive effects of HO-1 induction, biliverdin,
and CO in reducing sickle blood adherence and in promoting vasodilation, indicating the need
to further explore the therapeutic potentials of the HO pathway in the treatment of SCD [64].
The human HO-1 is comprised of a protein fold that primarily contains α-helices. The heme
is held between two of these helices (Figure 3b). HO-1 acts as a cytoprotective stress protein
and provides defense against oxidative stress associated with sickle cell disease by accelerating
the degradation of pro-oxidant heme and hemo proteins to the radical scavenging bile
pigments, biliverdin, and bilirubin [65]. HO-1 helps the body’s defense in response to physical
stress. The levels of heme are strictly controlled by the balance between heme biosynthesis and
catabolism as indicated in Figure 4 [65]. The key factor in the transcriptional activation of HO-1
is transcription factor Nrf2 (Figure 4). It interacts with many other genes that encode phase II
drug-metabolizing enzymes so as to respond to oxidative stress [68].
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Figure 3. (a) The Heme oxygenase system. Source: [66]. (b) The Heme oxygenase system. Source: [67].
Figure 4. Regulation of HO-1 induction by transcription factors and kinases. Source: [69].
Sickle hemoglobin induces the expression of heme oxygenase-1 (HO-1) in hematopoietic cells
through a mechanism that involves the ubiquitination-degradation of Kelch-like ECH-
associated protein 1 (Keap1), a cytoplasmic repressor of the transcription factor NF-E2-related
factor-2 (Nrf2). Upon nuclear translocation, Nrf2 binds to the stress-responsive elements in the
Hmox1 promoter, a regulatory mechanism that plays a central role in the control of Hmox1
expression in response to heme [70]. Moreover, the higher rate of free heme released from sickle
versus normal human subjects, in the absence of inflammation, induces HO-1 expression
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without causing cytotoxicity and this explains how sickle human Hb may also cause the
expression of HO-1 in human and mouse peripheral blood mononuclear cells and in human
endothelial cells as well [54]. Although a link between sickle cell disease and resistance to
severe malaria is well established, the biochemical relationship between the two is unknown.
3.4. Inducible nitric oxide synthase
Nitric oxide (NO) also influences the outcome of sickle cell disease. This outcome may
sometimes be beneficial to SCD patients, provided there is increase in the production of
endogenous NO so as to prevent the release of hemoglobin during hemolysis [7]. Inducible
nitric oxide synthase (iNOS) is not normally expressed in the cells, but can be induced by the
action of bacterial endotoxins (lipopolysaccharide), cytokines, and other agents. Though it is
mainly identified in macrophages, iNOS expression may be stimulated in virtually any cell or
tissue type, provided the appropriate inducing agents have been identified [71]. Upon its
expression, iNOS remains constantly active and independent of intracellular Ca2+ concentra-
tions. Cell and tissue damage can be linked to the NO radical itself or NO interaction with O2-•
resulting in the formation of peroxynitrite (ONOO-). Most of the inflammatory and autoim-
mune lesions are characterized by large amounts of activated macrophages and neutrophils.
NO can be secreted in large quantities by the cells, causing damage to the surrounding tissues
[72].
Figure 5. Structure of NOS monomers (A) and the functional dimer (B) Source: [71].
Finally, the excessive production of NO by iNOS plays a critical role in septic shock. This
condition is characterized by massive microvascular lesions, arteriolar vasodilatation, and
hypotension. Symptoms are usually initiated by bacterial endotoxins. Nonetheless, decrease
in blood pressure can occur as a result of excessive production of NO by iNOS induced in the
vascular wall [73]. In mammals, nitrous oxide (NO) is produced by the calcium-calmodulin-
regulated constitutive isoenzymes eNOS (endothelial NOS) and nNOS (neuronal NOS), while
the inducible isoform, iNOS, binds to calmodulin at physiologically significant concentrations
producing NO free radicals as an immune defense mechanism (this is the direct cause of septic
shock), and it may also play a role in autoimmune diseases. NOS-derived NO represents most
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of the NO produced in the vasculature and is associated with plasma membranes around cells
including the membranes of red blood cells [71]. The structure and catalytic mechanisms of
functional NOS are shown in Figure 5.
4. Conclusion
In conclusion, it is worthwhile to increase the search for potential plants that could supply
bioactive compounds useful for the treatment of sickle cell disease. More so, concerted efforts
are needed to further generate drugs to complement the already few drugs in existence, while
taking into account the synergistic effect on these bioactives. This will help to standardize the
administration of the bioactives to avoid any impediment to health due to overdose. Further-
more, it is necessary to exploit understanding of the interaction of these bioactives with the
genes of sickle cell disease patient to increase our chances of getting a permanent solution to
the disease. Geographical spread of these identified antisickling plants contributes to low levels
of sickle cell patients where the potentials are known. More efforts should therefore be
channeled toward increasing awareness about the plants.
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